Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice
about
Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccineCurrent ebola vaccinesEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentPEGylated Adenoviruses: From Mice to MonkeysEbola virus vaccines: an overview of current approachesInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionMouse models for filovirus infectionsAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesAdenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenzaA novel recombinant Peste des petits ruminants-canine adenovirus vaccine elicits long-lasting neutralizing antibody response against PPR in goatsPre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutininUse of recombinant adenovirus vectored consensus IFN-α to avert severe arenavirus infectionTherapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201)Production of adenovirus vectors and their use as a delivery system for influenza vaccines.Ebola and Marburg virus vaccines.Adenoviral vectors as novel vaccines for influenza.Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in MiceDevelopment of adenoviral vector-based mucosal vaccine against influenza.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesThe influence of innate and pre-existing immunity on adenovirus therapyOral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.Development of replication-competent viral vectors for HIV vaccine delivery.Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.Vaccination with recombinant adenoviruses expressing the peste des petits ruminants virus F or H proteins overcomes viral immunosuppression and induces protective immunity against PPRV challenge in sheep.Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.Enhancing mucosal immunity in mice by recombinant adenovirus expressing major epitopes of porcine circovirus-2 capsid protein delivered with cytosine-phosphate-guanosine oligodeoxynucleotidesComparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China.Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse modelProtective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.Effects of nasal or pulmonary delivered treatments with an adenovirus vectored interferon (mDEF201) on respiratory and systemic infections in mice caused by cowpox and vaccinia viruses.Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model.Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection.HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunitymiRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigensEfficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.Filovirus vaccines.
P2860
Q21134724-06B6C1CC-1C38-4069-A428-2A3A51701FF0Q21534720-E1B498E5-763F-4842-8CA7-974921AE39A1Q24597625-35AF6AC8-D0B4-4B15-893B-1A7909B17625Q24635276-399A9622-ABAB-4D3C-8FFA-D5013935F587Q26999232-B9156131-FBDF-47CD-9183-1790E689B4E3Q27001897-A7390545-A8C0-4799-9718-6B76C26610FDQ27011569-85F6B445-1DD8-4680-8BE0-BBB125450F8CQ27013568-AFFB9019-707C-4659-AB08-A0CB84B8CCA8Q28479491-EE064AAC-5CFB-4584-8F96-44C8493776F7Q28729865-CC74B70A-3B26-4069-9F40-B607CA0E23B4Q28731982-A95630AF-D3A4-4C70-ACE5-C5F0B71D5BE6Q28743512-88E2A167-213F-420A-9CFA-7827857B96E0Q28743894-7FCA9E07-16CE-4931-8AE6-6D04217F5754Q30226988-836C4A2E-30C8-4A11-85E6-5A0F40831322Q30234637-3C7F6567-8CC0-47F8-B134-E71112B3A3DDQ30370445-656E2A7D-D1F5-4FCE-9C47-0FF1FB43B401Q30375982-EB120939-9A28-4E72-8CB6-6B37D8E8A44AQ30386196-AEB1A027-02CF-4EEC-BCF5-85BEA5216E2EQ30396642-6504098D-BEC7-4AD3-A8B7-9BB735E4E55DQ30427591-C9DD5E07-78C4-48C3-A4F9-58F1C5A0FF0DQ33655401-BDA83E27-AD88-470D-A252-5BDC484762ADQ33686890-9279DC67-B09B-47CB-A022-DADF62D60752Q33694226-BAACD749-B89D-49D9-A1F2-B21A690F35F2Q33743800-B1CC6D25-8CAE-4819-A4A1-200B5D30D9E0Q33858681-A589D788-F61D-4E34-8AC1-B517FB3D5210Q33889779-78FE3763-CEB1-4FC5-AD90-AED3688129F6Q34059627-1DE18AF3-8274-4D23-8AAE-8AE256E50725Q34072792-D1401E2D-2174-4497-BEBD-F6F7BE6C7CAEQ34258568-67C2D731-D21B-4954-B782-8D3AA5C30279Q34289005-2073B99B-0979-4154-BF62-4481E376A783Q34478750-84B009A5-7FB2-44A8-B232-7B55E69D0742Q34701517-9E66F7FA-3D7C-4BC9-9928-6C079A6D52E9Q34781602-FF273D4C-5E5F-45A8-851D-824EF24DDAFAQ34850450-CC7BAB62-CE37-4B91-866B-5761C9E93B20Q34933362-F5C6D02B-7576-4DB9-A983-6D4713665A6BQ35005641-72982725-CD7D-4F7B-BFA6-6B062B7F3A54Q35108680-4B01D54D-F665-414D-88FF-4D17D285AC5DQ35144457-EFB646AD-F328-4499-8D5C-534A47B80CD2Q35221206-78AE1C18-2C6F-4752-B220-55FB80BFD2FDQ35558539-97779B75-B6D2-4F7F-B144-E4FE0B72D81E
P2860
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Nasal delivery of an adenoviru ...... es the immune response in mice
@ast
Nasal delivery of an adenoviru ...... es the immune response in mice
@en
Nasal delivery of an adenoviru ...... es the immune response in mice
@en-gb
Nasal delivery of an adenoviru ...... es the immune response in mice
@nl
type
label
Nasal delivery of an adenoviru ...... es the immune response in mice
@ast
Nasal delivery of an adenoviru ...... es the immune response in mice
@en
Nasal delivery of an adenoviru ...... es the immune response in mice
@en-gb
Nasal delivery of an adenoviru ...... es the immune response in mice
@nl
altLabel
Nasal Delivery of an Adenoviru ...... es the Immune Response in Mice
@en
prefLabel
Nasal delivery of an adenoviru ...... es the immune response in mice
@ast
Nasal delivery of an adenoviru ...... es the immune response in mice
@en
Nasal delivery of an adenoviru ...... es the immune response in mice
@en-gb
Nasal delivery of an adenoviru ...... es the immune response in mice
@nl
P2093
P2860
P3181
P1433
P1476
Nasal delivery of an adenoviru ...... es the immune response in mice
@en
P2093
James E Strong
Kaylie N Tran
Maria A Croyle
Michael Gray
P2860
P3181
P356
10.1371/JOURNAL.PONE.0003548
P407
P577
2008-01-01T00:00:00Z